Adamantios Mamais

Adamantios Mamais

CO RES AST PROF

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-5550

Publications

2020
LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.
Science translational medicine. 12(565) [DOI] 10.1126/scitranslmed.aay0399. [PMID] 33055242.
2020
Sequential screening nominates the Parkinson’s disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
Neurobiology of disease. 141 [DOI] 10.1016/j.nbd.2020.104948. [PMID] 32434048.
2020
The Parkinson’s Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network.
Cell reports. 31(5) [DOI] 10.1016/j.celrep.2020.107614. [PMID] 32375042.
2020
LRRK2 mediates tubulation and vesicle sorting from lysosomes.
Science advances. 6(46) [DOI] 10.1126/sciadv.abb2454. [PMID] 33177079.
2019
Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2.
Neurochemical research. 44(6):1446-1459 [DOI] 10.1007/s11064-018-2650-4. [PMID] 30291536.
2019
Genetic analysis of neurodegenerative diseases in a pathology cohort.
Neurobiology of aging. 76:214.e1-214.e9 [DOI] 10.1016/j.neurobiolaging.2018.11.007. [PMID] 30528841.
2019
LRRK2 links genetic and sporadic Parkinson’s disease.
Biochemical Society transactions. 47(2):651-661 [DOI] 10.1042/BST20180462. [PMID] 30837320.
2019
Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.
Neurobiology of disease. 129:67-78 [DOI] 10.1016/j.nbd.2019.05.012. [PMID] 31102768.
2018
Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson’s disease brains with Lewy body pathology.
Brain research. 1701:75-84 [DOI] 10.1016/j.brainres.2018.07.023. [PMID] 30055128.
2018
Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity.
NPJ Parkinson's disease. 4 [DOI] 10.1038/s41531-018-0049-1. [PMID] 29707617.
2018
mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition.
Bioscience reports. 38(2) [DOI] 10.1042/BSR20171669. [PMID] 29563162.
2018
Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice.
Human molecular genetics. 27(18):3257-3271 [DOI] 10.1093/hmg/ddy232. [PMID] 29917075.
2017
Hexokinases link DJ-1 to the PINK1/parkin pathway.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-017-0212-x. [PMID] 28962651.
2016
mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1.
Scientific reports. 6 [DOI] 10.1038/srep35106. [PMID] 27731364.
2014
A Parkinson’s disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Human molecular genetics. 23(18):4887-905 [DOI] 10.1093/hmg/ddu202. [PMID] 24794857.
2014
Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution.
The Journal of biological chemistry. 289(31):21386-400 [DOI] 10.1074/jbc.M113.528463. [PMID] 24942733.
2014
GTP binding controls complex formation by the human ROCO protein MASL1.
The FEBS journal. 281(1):261-74 [DOI] 10.1111/febs.12593. [PMID] 24286120.
2014
LRRK2: dropping (kinase) inhibitions and seeking an (immune) response.
Journal of neurochemistry. 129(6):895-7 [DOI] 10.1111/jnc.12691. [PMID] 24661004.
2014
Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7.
Nature communications. 5 [DOI] 10.1038/ncomms6827. [PMID] 25500533.
2014
Dysregulation of glucose metabolism is an early event in sporadic Parkinson’s disease.
Neurobiology of aging. 35(5):1111-5 [DOI] 10.1016/j.neurobiolaging.2013.11.001. [PMID] 24300239.
2013
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson’s disease brains with Lewy Body pathology compared to idiopathic cases.
Neurobiology of disease. 58:183-90 [DOI] 10.1016/j.nbd.2013.05.017. [PMID] 23747310.
2013
Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus.
PloS one. 8(8) [DOI] 10.1371/journal.pone.0070724. [PMID] 23967090.
2013
Inhibition of LRRK2 kinase activity stimulates macroautophagy.
Biochimica et biophysica acta. 1833(12):2900-2910 [DOI] 10.1016/j.bbamcr.2013.07.020. [PMID] 23916833.
2013
Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation.
Biochemical and biophysical research communications. 441(4):862-6 [DOI] 10.1016/j.bbrc.2013.10.159. [PMID] 24211199.
2012
Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.
PloS one. 7(10) [DOI] 10.1371/journal.pone.0047784. [PMID] 23082216.
2011
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies.
Acta neuropathologica. 122(4):415-28 [DOI] 10.1007/s00401-011-0857-4. [PMID] 21773886.
2011
Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.
PloS one. 6(7) [DOI] 10.1371/journal.pone.0022489. [PMID] 21799870.
2009
Relationship of p21-activated kinase (PAK) and filopodia to persistence and oncogenic transformation.
Journal of cellular physiology. 220(3):576-85 [DOI] 10.1002/jcp.21788. [PMID] 19384897.
2007
Acetylation increases access of remodelling complexes to their nucleosome targets to enhance initiation of V(D)J recombination.
Nucleic acids research. 35(18):6311-21 [PMID] 17881376.
View on: PubMed
2003
Regulation of V(D)J recombination by nucleosome positioning at recombination signal sequences.
The EMBO journal. 22(19):5197-207 [PMID] 14517257.
View on: PubMed
2002
Antarctic Dry Valley mineral soils contain unexpectedly high levels of microbial biomass.
Extremophiles : life under extreme conditions. 6(5):431-6 [PMID] 12382121.
View on: PubMed

Education

PhD in Neuroscience
2005-2010 · UCL Institute of Neurology, U.K.
MSc in Molecular Medicine
2001-2002 · University College London, U.K.
BSc in Molecular Biology
1998-2001 · University College London, U.K.

Contact Details

Phones:
Business:
(352) 273-5550